Media Contacts:
Daniel Katzman
President
617.331.4111
info@NeuroHealing.com
Company Information:
NeuroHealing Pharmaceuticals Inc.
50 Undine Road
Suite #1
Newton, MA 02135
USA Ph.617.331.4111
Fx. 617.777.1267
NeuroHealing Pharmaceuticals Inc.
Internet:
info@neurohealing.com
http://www.neurohealing.com
NeuroHealing develops and commercializes novel therapeutics based on new formulation strategies to treat the needs of post-acute neurorehabilitation patients, including disorders such as traumatic brain injury, stroke, Parkinson’s disease and other motor neuron diseases.
Recent Company Headlines
- 08/21/09 - NeuroHealing Announces Formation Of Medical Advisory Board For NH02D Program
- 04/13/09 - NeuroHealing to Present Data on NH02D Premature Ejaculation Drug at AUA Meeting
- 02/02/09 - NeuroHealing Appoints David Gwynne, Vice President Business Development
- 09/24/08 - Oct. 6-7: NeuroHealing Pharmaceuticals To Present At Drug Repositioning Summit In Boston
- 08/11/08 - Industry Leaders Select NeuroHealing's NH001 Among Top Ten Most Promising Neuroscience Projects Available For Partnering
- 07/22/08 - Life Science Angels Makes Additional Investment In NeuroHealing Pharmaceuticals
- 02/19/08 - NeuroHealing Pharmaceuticals initiates Phase II Clinical Trial of NH004 for Sialorrhea Control in Parkinson's Disease Patients
- 01/03/08 - NeuroHealing Pharmaceuticals Appoints Burt Adelman, M.D., To Board Of Directors
- 12/13/07 - The Michael J. Fox Foundation Awards Funding To NeuroHealing Pharmaceuticals Researchers for a Phase II Clinical Trial of NH004 for Sialorrhea Control in Parkinson's Disease Patients
- 03/12/07 - NeuroHealing Pharmaceuticals Presents Clinical Data For NH001 In Coma Recovery At The American Society For Experimental NeuroTherapeutics Annual Meeting
- 09/12/06 - NeuroHealing Pharmaceuticals CEO, Neal Farber, To Speak At The Dow Jones VentureWire Health Care Innovations 2006 Conference, The Biotech & Life Sciences Global Venture Congress 2006, And The Life Sciences Venture Summit 2006
- 05/25/06 - NeuroHealing Receives FDA Orphan Drug Designation For NH001 For The Treatment Of Patients In A Vegetative State Or Minimally Conscious State Following Brain Injury
- 11/03/05 - NeuroHealing Pharmaceuticals To Present At Rodman & Renshaw Techvest Seventh Annual Healthcare Conference, Nov. 8
- 08/31/05 - NeuroHealing Pharmaceuticals Announces IND Submission For NH001 To Improve The Outcome Of Patients In A Vegetative State Following A Traumatic Brain Injury
- 12/08/04 - NeuroHealing Commences Clinical Trial Of NH001 For Coma Patients
This company has no media releases.
